{
    "relation": [
        [
            "",
            "EFV600mg Participants With Mild Hepatic Impairment",
            "EFV600mg Participants With Moderate Hepatic Impairment",
            "EFV600mg Participants With Severe Hepatic Impairment",
            "EFV600mg Participants With Normal Hepatic Function",
            "Not Dosed"
        ],
        [
            "Description",
            "No text entered.",
            "No text entered.",
            "No text entered.",
            "No text entered.",
            "No text entered."
        ]
    ],
    "pageTitle": "Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00162097?sect=X40156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981576.7/warc/CC-MAIN-20150728002301-00318-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 877285863,
    "recordOffset": 877271948,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups 21 participants were enrolled in the study; 5 discontinued prior to study drug administration (1 adverse event, 1 enrollment completed, 1 screen failure, 1 no longer met study criteria and 1 withdrew consent). Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: efavirenz containing antiretroviral regimen Intervention: HIV Infections Hepatic Impairment Conditions: Allocation:\u00a0Non-Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Pharmacokinetics\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type:",
    "textAfterTable": "\u00a0 \u00a0 EFV600mg Participants With Mild Hepatic Impairment \u00a0 \u00a0 EFV600mg Participants With Moderate Hepatic Impairment \u00a0 \u00a0 EFV600mg Participants With Severe Hepatic Impairment \u00a0 \u00a0 EFV600mg Participants With Normal Hepatic Function \u00a0 STARTED \u00a0 \u00a0 6 [1] \u00a0 2 [1] \u00a0 1 [1] \u00a0 7 [2] COMPLETED \u00a0 \u00a0 6 \u00a0 \u00a0 2 \u00a0 \u00a0 1 \u00a0 \u00a0 6 \u00a0 NOT COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 1 \u00a0 Participant no longer met study criteria \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}